Concepts (116)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Rheumatology | 7 | 2021 | 1213 | 1.01 | Why? |
| Rheumatic Diseases | 8 | 2021 | 2675 | 0.98 | Why? |
| Spondylarthritis | 3 | 2019 | 174 | 0.90 | Why? |
| Antirheumatic Agents | 6 | 2021 | 3023 | 0.60 | Why? |
| Spondylitis, Ankylosing | 1 | 2018 | 231 | 0.58 | Why? |
| Biosimilar Pharmaceuticals | 1 | 2018 | 205 | 0.57 | Why? |
| Terminology as Topic | 1 | 2018 | 546 | 0.48 | Why? |
| Registries | 7 | 2021 | 12327 | 0.37 | Why? |
| Immunity, Cellular | 1 | 2021 | 3614 | 0.34 | Why? |
| Immunity, Humoral | 1 | 2021 | 4849 | 0.31 | Why? |
| Myositis | 2 | 2018 | 185 | 0.29 | Why? |
| Sacroiliac Joint | 2 | 2019 | 26 | 0.25 | Why? |
| Anti-Inflammatory Agents | 1 | 2018 | 6153 | 0.19 | Why? |
| Myostatin | 1 | 2017 | 2 | 0.19 | Why? |
| Dermatomyositis | 1 | 2021 | 193 | 0.18 | Why? |
| Certolizumab Pegol | 1 | 2018 | 36 | 0.18 | Why? |
| Joint Diseases | 1 | 2019 | 122 | 0.18 | Why? |
| Arthritis, Rheumatoid | 3 | 2021 | 2043 | 0.17 | Why? |
| Magnetic Resonance Imaging | 3 | 2019 | 6551 | 0.17 | Why? |
| Severity of Illness Index | 8 | 2021 | 48226 | 0.17 | Why? |
| Back Pain | 1 | 2018 | 115 | 0.17 | Why? |
| Neuromuscular Diseases | 1 | 2017 | 303 | 0.13 | Why? |
| Reference Standards | 1 | 2018 | 1163 | 0.13 | Why? |
| Patient Outcome Assessment | 1 | 2018 | 707 | 0.13 | Why? |
| Interleukin-17 | 1 | 2018 | 602 | 0.13 | Why? |
| Musculoskeletal Diseases | 1 | 2020 | 646 | 0.12 | Why? |
| Lupus Erythematosus, Systemic | 2 | 2020 | 1380 | 0.12 | Why? |
| Extracellular Traps | 1 | 2021 | 1036 | 0.11 | Why? |
| Muscle, Skeletal | 1 | 2018 | 915 | 0.11 | Why? |
| Data Collection | 1 | 2021 | 1769 | 0.11 | Why? |
| Glucocorticoids | 3 | 2021 | 4431 | 0.10 | Why? |
| Phenotype | 1 | 2021 | 4037 | 0.10 | Why? |
| Lymphocytes | 1 | 2021 | 3056 | 0.09 | Why? |
| Guillain-Barre Syndrome | 1 | 2021 | 1495 | 0.09 | Why? |
| Antimalarials | 1 | 2020 | 2505 | 0.09 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2018 | 2483 | 0.09 | Why? |
| Europe | 2 | 2021 | 12702 | 0.08 | Why? |
| Humans | 22 | 2021 | 930598 | 0.07 | Why? |
| Disease Progression | 2 | 2021 | 13580 | 0.06 | Why? |
| Internet | 1 | 2021 | 6204 | 0.06 | Why? |
| Biomedical Research | 1 | 2021 | 5270 | 0.05 | Why? |
| Sacroiliitis | 1 | 2019 | 24 | 0.05 | Why? |
| Spondylarthropathies | 1 | 2020 | 163 | 0.05 | Why? |
| Interferon-Induced Helicase, IFIH1 | 1 | 2021 | 245 | 0.05 | Why? |
| Odds Ratio | 2 | 2021 | 5861 | 0.05 | Why? |
| Protein Tyrosine Phosphatases, Non-Receptor | 1 | 2017 | 5 | 0.05 | Why? |
| Myopathies, Structural, Congenital | 1 | 2017 | 6 | 0.05 | Why? |
| Inflammation | 2 | 2018 | 13255 | 0.05 | Why? |
| Cytokines | 1 | 2021 | 15010 | 0.05 | Why? |
| Activin Receptors, Type II | 1 | 2017 | 20 | 0.05 | Why? |
| Follistatin | 1 | 2017 | 25 | 0.05 | Why? |
| Absorptiometry, Photon | 1 | 2018 | 168 | 0.04 | Why? |
| Pandemics | 5 | 2021 | 389249 | 0.04 | Why? |
| Adult | 9 | 2021 | 244371 | 0.04 | Why? |
| Male | 11 | 2021 | 367725 | 0.04 | Why? |
| Stakeholder Participation | 1 | 2021 | 481 | 0.04 | Why? |
| Female | 11 | 2021 | 380317 | 0.04 | Why? |
| Induction Chemotherapy | 1 | 2018 | 149 | 0.04 | Why? |
| Global Health | 1 | 2021 | 13911 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.04 | Why? |
| Prednisone | 1 | 2020 | 652 | 0.04 | Why? |
| Spine | 1 | 2018 | 292 | 0.04 | Why? |
| Hospitalization | 3 | 2021 | 54280 | 0.04 | Why? |
| Janus Kinase Inhibitors | 1 | 2020 | 682 | 0.03 | Why? |
| Child | 2 | 2021 | 70012 | 0.03 | Why? |
| Protective Factors | 1 | 2020 | 1720 | 0.03 | Why? |
| Arthritis, Psoriatic | 1 | 2020 | 625 | 0.03 | Why? |
| Vasculitis | 1 | 2020 | 691 | 0.03 | Why? |
| Middle Aged | 9 | 2021 | 270681 | 0.03 | Why? |
| Positron-Emission Tomography | 1 | 2018 | 802 | 0.03 | Why? |
| Mice, Knockout | 1 | 2017 | 1815 | 0.03 | Why? |
| Reproducibility of Results | 2 | 2019 | 11304 | 0.03 | Why? |
| Immunosuppressive Agents | 2 | 2020 | 6331 | 0.03 | Why? |
| Down-Regulation | 1 | 2017 | 1416 | 0.03 | Why? |
| Exanthema | 1 | 2021 | 1097 | 0.03 | Why? |
| Dose-Response Relationship, Drug | 1 | 2020 | 3776 | 0.03 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 1454 | 0.03 | Why? |
| Lung Diseases, Interstitial | 1 | 2021 | 1476 | 0.02 | Why? |
| Radiography | 1 | 2018 | 1576 | 0.02 | Why? |
| Aged | 6 | 2021 | 215776 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2020 | 5440 | 0.02 | Why? |
| Internationality | 1 | 2021 | 3297 | 0.02 | Why? |
| Double-Blind Method | 1 | 2018 | 5988 | 0.02 | Why? |
| Oxygen Inhalation Therapy | 1 | 2020 | 3629 | 0.02 | Why? |
| Young Adult | 3 | 2021 | 93724 | 0.02 | Why? |
| Biological Products | 1 | 2020 | 2331 | 0.02 | Why? |
| Respiration, Artificial | 2 | 2021 | 22116 | 0.02 | Why? |
| Gene Expression Regulation | 1 | 2017 | 4020 | 0.02 | Why? |
| Prognosis | 2 | 2018 | 32490 | 0.02 | Why? |
| Prospective Studies | 2 | 2021 | 43301 | 0.02 | Why? |
| Societies, Medical | 1 | 2020 | 6907 | 0.02 | Why? |
| Pneumonia, Viral | 3 | 2020 | 243684 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2018 | 9537 | 0.02 | Why? |
| Coronavirus Infections | 3 | 2020 | 253789 | 0.02 | Why? |
| Ultrasonography | 1 | 2018 | 4409 | 0.01 | Why? |
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 5002 | 0.01 | Why? |
| Case-Control Studies | 1 | 2020 | 17671 | 0.01 | Why? |
| Risk Factors | 2 | 2020 | 71621 | 0.01 | Why? |
| United Kingdom | 1 | 2021 | 18046 | 0.01 | Why? |
| Adolescent | 2 | 2021 | 86841 | 0.01 | Why? |
| Disease Models, Animal | 1 | 2017 | 10998 | 0.01 | Why? |
| Social Media | 1 | 2021 | 5798 | 0.01 | Why? |
| Prevalence | 1 | 2021 | 25773 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2018 | 10649 | 0.01 | Why? |
| Cohort Studies | 1 | 2021 | 36005 | 0.01 | Why? |
| Quality of Life | 1 | 2018 | 9820 | 0.01 | Why? |
| Comorbidity | 1 | 2021 | 34796 | 0.01 | Why? |
| Time Factors | 1 | 2018 | 31397 | 0.01 | Why? |
| United States | 1 | 2021 | 46150 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2021 | 53120 | 0.01 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.01 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.01 | Why? |
| Treatment Outcome | 1 | 2018 | 51732 | 0.01 | Why? |
| Aged, 80 and over | 1 | 2021 | 88759 | 0.01 | Why? |
| Retrospective Studies | 1 | 2021 | 105322 | 0.01 | Why? |
| Animals | 1 | 2017 | 78931 | 0.01 | Why? |
Machado's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(116)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(211)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_